Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia

New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) :

• Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP
• Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP
• Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP
• Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP
• Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP

Inclusion Criteria:

• Age from 18 to 50 years old
• Singleton pregnancies between 20 and 41 weeks of gestation
• Preeclampsia
• Normal pregnancy

Exclusion Criteria:

• Age<18
• Infectious disease: HIV, HBV or HCV
• Multiple pregnancies
• Opposition of the patient